• Tidak ada hasil yang ditemukan

BPUMS-v11n2p98-fa.pdf

N/A
N/A
Protected

Academic year: 2024

Membagikan "BPUMS-v11n2p98-fa.pdf"

Copied!
10
0
0

Teks penuh

(1)

! " #$

%& ' ( ()* $+%

! ", -. /%

%0# 1 ", "2#3 01 ' ! " #$ 4 . 5 ,3 6 7 8

9# :

; : )-<

=>?

@A ) -73

=CA?

(

:E 3 1 :F%G H3%0* H 1 *3 :H3%0** / I 2,J "7 0 " 5

K : . M : OCPC

=P=QQ [email protected] :

Email

" R H 1 S3 G "T3 * % UV*

2G 3 ",J

@ / (W,3

6 7 3 , 2 /

$ 0 3 X %YG3 " . :=

4 7 Z 9)

%-< ( < :; C/

:

%2G

/ % Z% .

P*

:

%2G

" X 3 7 :Q

%2G , 1 < ,3 %

"

O

# 3 # G=

1 J T / T 7

"

T [

"

: 5 / I 2,J "7 0 "

()* $G%

J%T\ 87\ ' ( /

H3%0* :

] ,3 ;

/ 3%2G / I 2,J T [T

"

: / I 2,J "7 0 " 5 H3%0* :

# 3 # GC

/J T 1 %[

/ I 2,J "7 0 " 5 H3%0* :

,3 P

I 2,J T [T

"

:

"7 0 " 5

/ I 2,J

H3%0* :

273Q

7 #

"

T 7

"

T [T

"

E ' WT ^ $G% : /

! ! 5 ,3

:

%0# 1

273O

1

# 9

"

: / I 2,J "7 0 " 5 H3%0* :

[_

: HJ H 1 E 3$ 3 S3 G "T3 * 1 R

"* G / 73 # `a

.

" b Z c 3 1 * 1 / 9,3 * c 3 3 H3 *

c d* % H 1 E 3$ 3 0

%G -273 G%* , / .

e 3

: 2G HJ H 1 H %1 f 1 g 1 7 :/ (W,3IX

", ,3 % T 5 2 7 %* % 1 $0] ", 1 /3 CMV)

( G

2G HJ " I H 1

# $ 0]* S3 G "T3 * 1 : #3 6%2 G )* 3 IX .

* 3 h V 7 )<

i : G%* , 3%j9 1 7 c 3

I 7 2G G H 1 R IX

S3 G ) 1 Yk 6%2 G H3 . (

97l I pcDNA3

) 1

"- 6%2 G H3 . (

c [- ,3%* /3%1

6 7 H3 9a* / _ %2

"

CHO) (

\ 7 2 %& 3%R -273 m(2 E .

6 7 G n )

,3%* / j1 j# [-

2G H 1 / 7 [#\ o

", ,3IX 3 h

; C p9

X% I H \ / \

%& 3%R (W,3 /3 .

2 :

"- 6%2 G 1 ( \ 7 1 2, 2G H 1 %5, 1

6 W IX

* 6 7 %& n7

# [- ,3%* / 1

97l G%* , / 1

. 6 7 %& H 1 H3$ " 3 213 (

# [- ,3%* / G%* , 7 1

H 1 E 3$ 3 %5, , :

6 7 n7 * / X G 73 "

2 S3 G "T3 * .

] 2, /% &

:

* %1 l.

V 1 %1 S3 G 3$ 3 E(, 2G H

WT ^ /3%1 "Y7 3$13 ", 1 / 97l ! 7 1 q% c 3 :IX

2G H 1 I * 92 7

", ,3IX

# 8 3% 6 W .

/ G H &J3 :

HJ :S3 G "T3 * 2G : G%* , c d* % :"* G /

IX

T ( :

;Q /

=;

/ AO T ( e% s :

P / C / A?

(2)

!"

#" $ %# & #' ( )

* + in vivo

ex vivo )

- .(

0 1%

22%

0 !3 4 3 ( 5 # 6'

7# 2%

7 1 $ %# & #' 8

!

9 : ( ( 5 #

. B 1 3

( ; 6 #%

7< = >? % @ # 6

% 3 A % B

C+ D

* + 8

E ( #% 6 F 1G H X

# !

IJJJJ / -

L #

) M .(

N 3 O ! 1

B 7 # <' ( 8 P #Q $ %#

R 6

.

$ %# C 8 S 0 !3

& #' # 2 & #' 2 ( $ %#

)

#+ 2 !L? <' (

2 !3 0 T % U2 )

I .(

V

7 1 U2 #+ 2 1%

%

2% #' P = C= WX % # Y D 8 )

Z [

\ .(

0L

# Y D %

% WX

8 7< = $

L 2 8 1 ( #X 2 6

%

#+ 2 U2

# Y D

WX %

] 22%

)

^ ( .

8 = 28 #+ 2

! _ U2 1% 0 % %

# #' C 8 V

0 !3

2 S

6 2 =

!

S

`

#3 #a

T 2 1' T

<

2 6 )

-J [ b .(

0 !3 U2 = 1Ac %

% 3 B

!" :

2 #% # #' U2 #+ 2 (

# 2 !

_ #% ) 1X

) --

-M .(

# <

%W d 8 = 28 #+ 2

# C c # Y D e '

I ' L

#f%

%

#+ 2

#c

# X _ U2 %

Q6 ( @

# L

) -J [ b .(

* % # _ U2 9 S 1 #'

]

# a

7 S = Xg

#c mRNA

) -I .(

<%

m7G 5 ) -\

(

7 S S =

-

mRNA

S A

: #V

h #8 % AUG )

(

# ) -e -Z -^

(

h #8 % "

) -b (

#A S 7 V

) -B

MJ ( ' i S > a = !

# h #8 %

) -^

M- MM ( - Xg

7 S (

* % mRNA

#'

# h #8 g # % 2 6 S 1

9 ] _ U2 T #c # a 22%

. S

S 1 ( j ( %

= 28

( U2 d 8

Xg

7 S =

#f% mRNA

* % h #8 _ U2 % S 1 #'

#

% k )

-Z MI .(

S

' L e

#f%

% 2 & #' WX

* +

GCC(A/G)CC l h #8 % ( CAc

# AUG ) (

#c

C 2 # X

C E ( A m h #8 % 28

2%

) -Z MI .(

n !X

@ k

%

0L o

S

?

%

# % # h #8

`

h p % #a

(3)

H3 [9 $ 0 3 X H 1 S3 G "T3 *

2G

@ t (W,3 /

=>>

j ( % S

! k )

M\

( .

# T % # i S C E!

Q % 9+ # i >?

2

# h #8 % )

M\

Me .(

* @S o

k l1 Q

j ( % S qD %

& #' 0 !3 $ 8

) MZ .(

%W $S o 0 !3 1 c j ( % S

& #' $ %#

. 0 g'

% 3 # i :

B

#c @

# h #8 % ( CAc j ( % S ATG ) (

% 3 ( 2

B

# 2 %

-

6 1X

) -- ( c

% 3 B

7 1 6

# 6 Q

CHO 2 r 3#X #c @S o

.

e 3

G

/%2+ 1 e 7 97l :H3 3 , 2 "T 7 i :

%9 3%

:

# N n 1% k #8

) g # [ s # T (

CD # # 6

(

8 )

. S 1 d

# S 1 5 ( 8 #= CHO

% 3 L 6' S 1 ! 2

B

3#X #c ) .

$ %# d(

pET26-

hFIX-I )

-- (

!3 L "S 2

#3 j ( % S T

PCR 2

8 )

.

<' O 9 pcDNA3

)

# 2 [

s # T (

d( D #V # ' % 2

% 3 B 7 1

) 6'

3#X #c .

(

8 =

T 6 2 5

t= 8 2

2 6 Q

.

# #' 8 )

O 9

# ( u#8 ST %#8 m

MWG

8 = .

8 $,\ : + n ) 9 # 3 :

+ "

:

kN m 9 LB

# N kN m 9 2

v

8 ) .

w T 1

C ' #' ! 6 %

( %i X IPTG )

Xgal ( )

$ #

U1Y -JJ IJ MJ MJ

5 E#X #

1 k% m 9 # S (

( * +

8 ) Q kN m 9

. _ ! T NotI

DraI T4 DNA Ligase 6 2

G-418 ) (

N

7 x9 t 1Q

<' PCR C

3 ks)6 # Z

N#8 ( n

) ST (

#=

#X . _ ! T BamHI

<'

y2 1%

pTZ57RT 8 #= ( 2 #3 (

.

<' N 3 c 3

B N#8 ( 6

"

) 6 #3 (

8 #=

. 6 @ AV <'

N 3 @ 6 _ :

B

# = 7 ( ( z * +

T . m 9 DMEM k%

{

Hams-F12 sA X %#8 (

) s # T (

8 L

CHO 7 1

8 )

.

7 /

DNA

/ :

DNA (

n | #

8 E ? y2 1N )

M^

.(

$ %# d(

pET26-hFIX-I

# f L "S 2

$ %# >@oc K-E1-I1-E2-4

) C 8 @oc

!X -

\ 7 S

% 3 cDNA B

4Luria-Bertani

Dulbecco’s modified Eagle’s medium

:

5'GGATCCGCCACCATGCA GCGCGTGAACATGAT 3´

hFIX-K-E1-F

5' CCT TGC AAC TGC CGCC ATTTA AAC 3'

hFIXE4-R

(4)

# 2 % -

C+ 3 D 1X

!X -

M

#c T (

8 )

.

S}

j ( % S 4 9

% 3 cDNA }

B

#c }

S #'

}

#

hFIX-K-E1-F 8 # W'

.

E ? U2

6 C

~ L (

e #' }

#

hFIX-K-E1-F hFIXE4-R

" $ #

BamHI ! T 8 D #V DraI

.

"T3 * c W*

:

6 j ( % S qD 9+

8 (

d(

pcDNA3-K-hFIX-I $ N#

)

(

S @

"

ABI 373 )

ST [

( MWG

# #' ( ) + x =

] #X .

c [- ,3%* 6 7 G :

CHO 7 1 I^

>

k3 #X

#)6 e CO2 % k% m 9 Hams-F12

A6 DMEM -

/ -

% -J + 2 E# (

U/ml X -JJ 2' G 1

100 µg/ml

'#

8 8 8 2Y 6

.

k 3 w S n k )6 # 1'

08

= 3#X * + .

U2 #

7 1

D CHO M\

ks)6 # 02N ( CAc

_% # JJJ / – -IJ JJJ / --J

= # ( 7 1

8 kN

. ks)6 # 02N # n

k 3 w S I

?l

3 [

?l

Z B^

' k% m 9

) c 3 T E#

5 (

* € 1Q e

c

* #D 4

8 #c

. 4 3 € 1Q

M

?g

$ %# <' € 1Q ( ;' 3 p

Cc D * IJ

8 #c 4 V c

.

L € 1Q

• 6 ;w

1 ml 7

M #X 3 p ' kN m 9

. ks)6 # 02N

* #

Cc D Z 3

.

;w m 9

k%

‚ ' T

k% m 9 7 1 C N

#X 3 p .

( E ks)k # ( ;' E

‚ # # kN m 9

( m 9 T

7 1 8 3 p .

3 ,3 2+ / (W,3 T W /% &

@

", ,3 :

N 3 ƒ S S @3 B

( ) 8

N 3 c 3 6 <' PTT B

7 @3

8

N#8 1 8 _ #3 C @S O o S

22%

#X @ .

% 3 S @3 ! Q #

B

( 8 6

8 )

%

@ S @3 ( ) e

c l1 Q (

<'

# 8

@ AV 6 ) -ZJ / - bJ / -

\J / - MJ / - -J / - ( "S E WY N 1 #

_ # @ (

8 .

@ 6 E ? #

-JJ

?l

(

?l

# -JJ c 3 <' (

N 3

?l

B -JJ PTT ( 7 @3

• c € 1Q 8

I

* #D c

I^

#X

#c

8 .

?l

;w -JJ

#1N _ 61N Me mM

CAc (

8 E#X I^

#X ( 3 p T

( @

8 # X

@ S @3 #

#

| #X @

.

2

I 7 ! 7 G%* , /

:

= }

$ %# d(

pcDNA3-K-hFIX-I

: }

# i }

% 3 } B S 1 d

\ CHO

* + % 3# W' * + 1D#

C 8 5 8

- 8 0 .

3Activated Partial Thromboplastine

(5)

H3 [9 $ 0 3 X H 1 S3 G "T3 *

2G

@ t (W,3 /

=>;

m[#

= : , / 7 ! 7 I * 9# mX3%

", 1 n73 X G%*

@oc ƒ 7 1D#

7 V IBI

% ( )

!X j ( % S D -

# 2 - 1X

!X M

\

% 3 K-E1-I1-E2-4 )

(

%

" !L?

! T n#

BamHI/DraI

n = L

( ) PCR

d(

pET26-hFIX-I $ %#

) -- (

"S 2

(6)

#X # f .

<' >@oc @ >1D#

pTZ57R/T 6

$ %# d( 8 (

pTZ57R/T- K-E1-I1-E2-4 T

. _q # '

( pTZ57R/T- K-E1-I1-E2-4 $ %#

pET26-hFIX )

-- ( _ ! T >1

BamHI/DraI

>@oc K-E1-I1-E2-4 $ %#

>@oc !"

E1-E2-4

$ %# d(

pET26-hFIX

$ %# d( #X

pET26-K-hFIX-I T

. 9+

=

d(

NW $ N#

( )

S sS ! S T ]

#X . ( ZBMI o= Cs8 ( )

$ %# d(

pET26-K-hFIX-I 1

_q

_ ! T X BamHI

XhoI N DraI

n# " ƒ m 3

$ %# d(

4 3

2 6 ] 8 ) C 8 M [ lS .(

>?

_q

pET26-K-hFIX-I d(

_ ! T

DraI /BamHI DraI /BamHI

@oc $ #

7 V

\^-

\eM eIMM -ZJ-

( )

U

8 k 7 _q ( ;' %

) C 8

M [ lS .(

2 :

[#

m

; : G%* , / 7 "T [T $ T ,\

. uT3 : G%* , i 7 pET26-k-hFIX-I

u

= : Hind III%G .

u

; : 97l

pET26

u :

C : G%* , i 7 pET26-K- hFIX-I

: u P : Q O : m[#

/

# "^!

pET26-K-hFIX-I *%* 1

1

BamHI NotI :

u :DraI

? : 43 * 8v K-hFIX-I-pET26 8 $,\ 1

BamH I u :DraI

A : 43 * 8v pET26-

hFIX-I BamHI 1

.NotI : G%* , i 7 pcDNA3-K-hFIX-I

. u

= :

%G 3 Y f Hind III u

; : 8v i 7

G%* , pcDNA3-K-hFIX-I BamHI 1

u C : 8v i 7 G%* , pcDNA3-K-hFIX-I NotI 1

u :

P : 43 * 8v

pcDNA3-K-hFIX-I BamHI 1

.NotI

1D#

#=T

m D $ %# d( _q

pET26-K-hFIX-I

<' pcDNA3

_ ! T

BamHI/NotI 6

cDNA (

$ %#

% 3 B

<' j( % S !L? %

pcDNA3

$ %# d( 8 E ?

pcDNA3- K-hFIX-I

T . 9+

=

$ %# d(

pcDNA3-K-hFIX-I

( )

S sS ! S T

) C 8 M [ F (

] S @

#X .

6 7 c [- ,3%*

CHO

/ 7 1 / G%* , :

:

# j ( % S #a # N 3

B

@

lS

M-MMZ e-\b MJM^

eZ\

- M I \ e Z ^ b M-MMZ

e-\b MJM^

eZ\

F

- M I \

(7)

H3 [9 $ 0 3 X H 1 S3 G "T3 *

2G

@ t (W,3 /

=>P

CHO 7 1 7 1

kN ( ;' 8 M\

_% # eJ

^J

:#… †o +

#

ks)6 # (

pcDNA3-hFIX- $ %#

) I -- pcDNA3-K-hFIX-I (

n ( )

k 3 w S )

2 3#X #c .

k )6 #

' <' pcDNA3 )

( ! )2 7# 2% 2

3# W' * + .

S # a] # :

T # j ( % kN m 9

7 1 8 )6 #

( E ks)6 # 02N ( ;' E

8 T

. 2

( $ %#

8 = 6 2

2 6

7 1 Q m 9 9 µg/ml U1Y

\JJ (

8 #c 6 2

# f (

7 1

#X #?2 <' .

‡# R

7 1 )6 #

k

( ;' ( 2r

6 2 .

S D : #… % 7 1

7 1 8 )6 #

c

7 1 %

\ e )

@ 21% 2r ( 0 7 1 (

C k $ %#

.

H 1 "7 %1 2G

@

", ,3 :

m 9

‚ kN

8 T

7 1 (

8 )6 # (

E ( ;' E

ks)6 # 02N L

S D

% 3 B

1D# ƒ @ 6 ( )

#

3#X #c 2

.

@ (

* )

ks)6 # 8 s)6 #

pcDNA3-hFIX-I Af 7# 2% 2

pCDNA3 7 1

k s)6 # 2

% 8 6 )2 7# 2%

#" k 2@ 0 N

@ (

8 )6 #

<'

% 3 22%

7# 2% 6 IX

)2 )

C 8 I ( .

m[#

C : 6 7 3 \ 7 1 G n ) / (W,3 T W "7 %1 G%* , i 7 1 # [- ,3%* /

pcDNA3-K-hFIX-I

1 (

6%2 G . 3 9, uT3 : PA c [- ,3%* 3 W1 . 7 .

3 9, :

?;

c [- ,3%* 3 W1 . 7 .

6 7 3 G n ) /

1 , [- ,3%*

6 7 3 G n ) N 1 # [- ,3%* /

pcDNA3 NC 1

# 3 H , ,3

.

†8# @ S @3

% 3 B m $ N#

7 1 kN m 9 8 s)6 #

k

. 7 1 m 9 @ ( 0 % )6 #

6 E ( j ( % S d( 8

7 1 m 9 Af 7# 2% 8 )6 #

]

# a

% 3 0 !3 j ( % S qD A

B

(8)

8T .

@ (

kN m 9 @ S @3

ks)6 # 02N # ( T (

$ %#

6 _ 7# 2N C 8

I z

8 .

% 3 ! 1 5 IX

@ AV = # S

7 @ 6

eJJJ 7 @ 2@ E#X

-JJ +

5 S S @3 )

eJ ( E#X -

+ S @3

5 S ( 3#X #U 8

) Mb .(

6

C 8 T E j ( % S I

F

k

% 3 †o %W S %

( IX MI +

\Z + ) ( --eJ E#X

MIJJ E#X

( V

^M 0 !3

.

w)1

1+ : j ( % S # a] # O 9

% 3 B

6 @

. 0 !3

& #'

( ( ) 2 ( $ %#

2 !3 0 U2 #+ 2 !L?

) I .(

C

_ U2 C =

• D

% # Y WX

3#X #c )

Z [

\ .(

% 8 tQk ( #

Xg

7 S =

* % mRNA -

#' S 1

# †o 6 ( ;' _ U2

L # )

-\

-Z -b -B .(

S =

mRNA 7 S S A

: #V

h #8 %

AUG ) ( Xg (

= - 7 S

L # # _ U2 % mRNA

) -^

[ -e .(

Xg ( j ( % S

=

7 S S

% * ? % mRNA

~ h #8 e

* % #f% T S 1 #'

% k # h #8 _ U2 3#X #c

) -Z MI .(

9+ # i S C E!

# h #8 % 2 Q %

) M\

.(

lc ˆ h #8 % ( CAc j ( % S

% D # ( *

\J s

% * ? E ( A

h #8 0 !3 h #8 % z 28 9+ WS 8

i # % 3

) Me .(

S

l * x

GCC(A/G)CC h #8 % ( CAc

7 S #f%

* % mRNA

#c S

2r # # X S

! #"

8 ) -Z MI MB .(

0L o

% 2 !"

0 (T

‰)D 8 z )1 Q

%W S k & #'

) -b IM [

IJ .(

0 (T j ( % S # G % 2%

#c # a] 9 & #' .

k * 9

l * + j ( % S %

GCC(A/G)CC )

' j ( % S (

( 9

mRNA 7 S 7 1

% C % V

8 ‰)D )

-I .(

" S I

[ A6

h #8 %

(GCC(A/G)CCAUG ) 1% 0

8 .

8 ‰)D • 8 " WS

V

% B^

7 S +

mRNA

* %

ST ( S

T g 2 '

A ) ( 6 "

2 ) -e .(

$S o

0 (T ( 6 %W

j ( % S #"

& #' 0 !3 1 c $ %#

. ( WS

S

# i L ! 2

#% ) & #' )

II .(

# k

h #8 % ? %

% 3 B

@ AV S D

' j ( % S k 6 % 8 … )D S

#c )

I\

.(

j ( % ' S ( WS

# i L

% 3 cDNA B

#% ) .

2 S 2r ( ) % #%Š E(i

# i L 1

% 3 cDNA

B

(9)

H3 [9 $ 0 3 X H 1 S3 G "T3 *

2G

@ t (W,3 /

=>O

k n !X 6

.

S # a]

-

face # U ( 5r % D # ( WX % C %

8 n !X 1% k #8 # % j )

MZ .(

D % 8 k * 9 T

# #' ( ) * + % #'

qD %

0 !3 j ( % S .

j ( % S # 2 L T % !

& #' l1 Q h # i $ %#

_ 6 8 %

. 0 g'

% 3 B

# #' 7# 2% 9 @ V CMV

% S qD !?

S 1 d j ( CHO

_ #% # .

T 7 S #f% %

7 1 mRNA

" % I

[ A6

l ( T ST ( h #8 %

GCCACC

" ST ( % I

[

_ #% ) .

# j ( % S #a # U2

N 3 B

@ CHO 7 1

kN m 9

‚ ( 8 T E

02N ( ;' E

ks)6 # L

S D

% 3 B

( )

1D# ƒ @ 6

3#X #c # .

(

@3 S

m 9 ( T @

‚ k%

1 ( 8 T 7

8 )6 #

(

S j ( % S c 3 $ %#

( $ # II /

^I II /

^Z 7 @ a Ie

MI +

ZB ZZ

7 @ a

Ie

\Z

<' S @3 +

# G 6 7 #

. S @3 @ ( * )

% 3 @ B

) m 9 (

‚ 8 T

7 1 ( ( 8 )6 #

k $ %#

% 3 * ) d 2 B

qD E qD

j ( % S .

S Af % * )

% 3 0 !3 j ( % B

k .

R

* 9 ( C+ D

% S 0 !3 j (

% 3 †8# S B

k% m 9 7 @3 ]

2%

. k R #" :#V ( S % 2

j ( %

# # i L $ 2 1

8 6

.

%[ * % (*

# #+ # % cT ( S X 26

(

= L

8 WX 6 @ AV <'

c +

2 .

References: __________________________________________________________

1.Garlick JA, Fenjves ES. Keratinocyte gene transfer and gene therapy. Crit Rev Oral Biol Med 1996; 7:204-21.

2. White SJ, Page SM, Margaritis P, et al.

Long-term expression of human clotting factor IX from retrovirally transduced primary human keratinocytes in vivo. Hum Gene Therapy 1998; 91187-95.

3. Makrides SC. Components of vectors for gene transfer and expression in mammalian cells. Protein Expr Purif 1999; 17:183-202.

4. Fong YW, Zhou Q. Stimulatory effect of splicing factors on transcriptional elongation.

Nature 2001; 414: 929-33.

5. Ismail SI, Kingsman SM, Kingsman, A J, et al. Split-Intron Retroviral Vectors: Enhanced

Expression with Improved Safety. J Virol 2000; 74:2365-71.

6. Rohrer J, Conley ME. Transcriptional Regulatory Elements within the first intron of bruton’s tyrosine kinase. Blood 1998; 91:

214-21.

7. Hirosawa S, Fahner J B, Salier JP, et al.

Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden.

Develop Biol 1990; 87: 4421–5.

8. Larizza A, Makalowski W, Pesole G, et al.

Evolutionary dynamics of mammalian mRNA untranslated regions by comparative analysis of orthologous human, artiodactyl and rodent gene pairs. Comput Chem 2002; 26:479-90.

(10)

9. Pesole G, Mignone F, Gissi C, et al.

Structural and functional features of eukaryotic mRNA untranslated regions. Gene 2001; 276:73-81.

10. Spicher A, Guicherit OM, Duret L, etal.

Highly conserved RNA sequences that are sensors of environmental stress. Mol Cell Biol 1998; 18:7371-73.

-- .

h ! Lk D

h ' # ( P | 2 6D

.

# a

# 2 -

# 6 1X

N 3 c B

@ 7 @3

7 1 ( 6

6' .

= 1?

e 8

\

‹ MI [ MJB

-M . P | 2 6D

# ( h ' 7<

. D #V

E ' 2 #N + x = N =

N 3 #

7 2 6 IX .

= 1?

I 8 -

‹ M^

[ -^

.

13. Kozak M. An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control. J Cell Biol 1991; 115:

887-903.

14. Shatkin AJ. Capping of eucaryotic mRNAs.

Cell 1976; 9 :645-53.

15. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes . Cell 1986; 44 :283-92.

16. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987; 196:

947-50.

17. Kozak M. Context effects and (inefficient) initiation at non-AUG codons in eucaryotic cell-free translation systems. Mol Cell Biol 1989; 9 :5073-80.

18 . Kozak M. Translation of insulin-related polypeptides from messenger RNAs with tandemly reiterated copies of the ribosome binding site. Cell 1983; 34 :971-8.

19. Kozak M. A short leader sequence impairs the fidelity of initiation by eukaryotic ribosomes . Gene Expression. 1991; 1 :111-5.

20. Kozak M. Effects of long 5' leader sequences on initiation by eukaryotic ribosomes in vitro. Gene Expression 1991; 1:

117-25.

21. Kozak M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc Natl Acad Sci USA 1986; 83:

2850-4.

22. Kozak M. Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes. Proc Natl Acad Sci

USA 1990; 87 :8301-5.

23. Kozak M. Regulation of protein synthesis in virusinfected animal cells. Adv Virus Res 1986; 31:229-92.

24. Kozak M. Recognition of AUG and alternative initiator codons is augmented by G in position 4 but is not generally affected by the nucleotides in positions 5 and 6. EMBO J 1997; 16:2482-92.

25. Harkins S, Cornell CT, Whitton JL.

Analysis of Translational Initiation in Coxsackievirus B3 Suggests an Alternative Explanation for the High Frequency of R+4 in the Eukaryotic Consensus Motif. J Virol 2005; 79: 987-96.

26. Michelon A , Michelon M, Simionatto S, et al. Effect of the kozak sequence on seroconversion of mice immunized with a DNA vaccine agenst swine colibacilosis. Braz J Microbiol 2003; 34: 85-7.

27. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. USA:

Cold spring harbor laboratory press, 2001.

28-Miao CH, Ohashi K, Patijn GA, et al.

Inclusion of the hepatic locus control region , an intron and untrranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Molecular Therapy 2000; 1:522-32.

29. Caveneer, Comparison of the consensus sequence flanking translational start sites in Drosophila and vertebrates. Nucleic Acids Res 1987, 15: 1353-61.

30.Johansen H, Schumperli D, Rosenberg M.

Affecting gene expression by altering the length and sequence of the 5' leader. Proc Natl Acad Sci USA 1984; 81:7698-702.

31. Kozak M. Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin invivo. Nature 1984; 308:241-6.

32. Kozak M. Selection of initiation sites by eukaryotic ribosomes: effect of inserting AUG triplets upstream from the coding sequence for preproinsulin. Nucleic Acids Res 1984;

12:3873-93.

33. Christopher R, Erwin M A, Helmrath C E, et al. Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection. Am J Physiol Gastrointest Liver Physiol 1999; 277: 440-533 34. Pang CP, Crossley M, Kent G, et al.

Comparative sequence analysis of mammalian factor IX promoters. Nucleic Acids Research 1990; 18:6722-31.

Referensi

Dokumen terkait